logo
Plus   Neg
Share
Email

AstraZeneca, Oxford Acknowledge Manufacturing Error In Potential COVID-19 Vaccine

astrazeneca oxford caccine 112620 lt

AstraZeneca and Oxford University are facing questions about the trial results of their investigational COVID-19 vaccine after they acknowledged a manufacturing error.

On Monday, AstraZeneca and the University of Oxford announced that the Coronavirus vaccine they are developing is 70 percent effective on average in a late-stage study conducted in the UK and Brazil. Surprisingly, the group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses.

The volunteers that were given the half-dose showed efficacy of 90%, compared to 62% efficacy when volunteers were given two full doses.

However, a day after the results were published AstraZeneca research chief Mene Pangalos reportedly said that difference in manufacturing processes led to some participants being given a half dose instead of a full one. This has raised questions about the vaccine's efficacy.

The British drugmaker's CEO Pascal Soriot on Thursday reportedly said that an additional study would be conducted to evaluate a lower dosage that performed better than a full amount in AstraZeneca's studies.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT